KOSPIBiotech & Pharma008490

Suheung

₩15,230▼ 1.49%2026-11-18 close
Market Cap
₩176.2B
Turnover
₩300M
Volume
20K
Shares out.
11.6M
PER
5.2×
PBR
0.4×
EPS
₩3,319
Dividend Yield
2.87%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩500 per share · Prices as of the 2026-11-18 close

01

Report overview

Suheung: Hard-Capsule Recovery Meets Uneven Quarterly Profit

Suheung is a capsule specialist with a dominant domestic hard-capsule share. Operating profit recovered in 2025 but fell again in the third quarter of 2026, so the durability of earnings is the next item to watch.

  1. 1

    Revenue reached KRW 722.3 billion in 2025, the largest year in 2022–2025, and rose for two consecutive years from 2024 to 2025.

  2. 2

    Operating profit bottomed at KRW 33.8 billion in 2024 and recovered to KRW 50.2 billion in 2025, up 48.3% year on year.

  3. 3

    Third-quarter 2026 operating profit was KRW 11 billion, down 19.7% year on year, while revenue rose only 1.8% over the same period.

  4. 4

    The debt-to-equity ratio edged down from 97.2% in 2022 to 96.1% in 2025, and total liabilities at the end of 2025 were KRW 520.1 billion.

  5. 5

    The price-to-book ratio sits below 1x, so whether the earnings recovery is sustained is the key variable in interpreting valuation.

02

Business structure

Suheung, founded in 1973, makes hard and soft capsules and covers gelatin and collagen raw materials, finished capsules and OEM/ODM work for health functional foods within one group.

A Thinkpool breakdown of the twelve months to the third quarter of 2025 shows health functional foods at 41%, hard capsules at 32%, raw materials at 16%, pharmaceuticals at 8% and cosmetics at 2%.

A WiseReport breakdown gives slightly different weights of 43.27%, 31.87%, 15.14% and 6.40%, so the sources differ at the decimal level. One report says capsules accounted for 82% of 2024 revenue. Domestic hard-capsule market share is reported at about 95% and global share at about 8%.

Hard-capsule exports were 77.31% of that segment's sales in December 2025, with the Vietnam plant serving demand in Southeast Asia and Europe. Health functional foods are mainly sold at home, but analysts point to fast-growing exports to China.

Customers are most domestic pharmaceutical firms and health-food makers, and the Korea IR Council flagged customer concentration as a risk. The group has 13 affiliates, including Suheung America, Suheung Vietnam, Suheung Japan and Suheung Europe GmbH.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩185B₩13.7B7.4%
2025Q4₩166.4B₩4.8B2.9%
2026Q1₩201.6B₩21.2B10.5%
2026Q2₩212.9B₩22.5B10.6%
2026Q3₩188.4B₩11B5.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩635B₩62B₩34B9.8%8.1%97.2%
2023₩594.6B₩43B₩6.1B7.2%1.4%108.3%
2024₩653.3B₩33.8B₩18.3B5.2%4.0%100.4%
2025₩722.3B₩50.2B₩43.5B7.0%8.9%96.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

On a disclosed annual basis, revenue fell from KRW 635 billion in 2022 to KRW 594.6 billion in 2023, down 6.4% year on year, then rose to KRW 653.3 billion in 2024 and KRW 722.3 billion in 2025, up 9.9% and 10.6% respectively, so revenue has grown for two consecutive years from 2024 to 2025.

Operating profit was largest in 2022 at KRW 62 billion and smallest in 2024 at KRW 33.8 billion, with 2023 at KRW 43 billion, down 30.6%, and 2025 at KRW 50.2 billion, up 48.3%. The operating margin moved from 9.8% in 2022 to 7.2% in 2023, 5.2% in 2024 and 7.0% in 2025.

In 2023, analysts pointed to customer losses and lower orders amid an economic slowdown, plus higher depreciation from hard-capsule expansion.

In 2024, the cost-of-sales ratio rose from 78.38% in 2022 to 84.20%, and the company's annual report cited higher raw material costs, weaker consumer demand from inflation and stronger global competition.

In 2025, hard-capsule profitability recovered to the low-to-mid 10% range in the second half, but a larger share of low-margin health functional foods, first-half inventory clearance and export-related costs held the full-year margin near 7%.

Profit attributable to controlling shareholders was KRW 34 billion in 2022, KRW 6.12 billion in 2023 (down 82.0%), KRW 18.3 billion in 2024 (up 198.7%) and KRW 43.5 billion in 2025 (up 138.0%), with growth in both 2024 and 2025.

Net income including non-controlling interests was KRW 47.1 billion in 2025, the gap versus controlling-shareholder profit reflecting minority interests.

Quarterly, operating profit went from KRW 13.7 billion in the third quarter of 2025 to KRW 4.82 billion in the fourth quarter, then KRW 21.2 billion in the first quarter of 2026, KRW 22.5 billion in the second quarter and KRW 11 billion in the third quarter.

Third-quarter 2026 revenue of KRW 188.4 billion was up 1.8% year on year, while operating profit was down 19.7%. Profit attributable to controlling shareholders for the last four quarters totals KRW 37 billion.

The debt-to-equity ratio was 96.1% at end-2025, with equity of KRW 541 billion and operating cash flow rising from KRW 56.2 billion in 2024 to KRW 76.9 billion in 2025.

05

Industry analysis

Hard capsules are a dosage form that uses gelatin and other raw materials, and demand follows pharmaceutical and health-food formulations. Suheung is described as the domestic maker that localized hard-capsule production after relying on imports, with a domestic share of about 95%.

A securities report from December 2023 put its global share at third place with about 7%. In overseas competition, production cost and utilization are the key factors, and one source notes that ten production units were added at the Vietnam plant in the third quarter of 2023.

Raw material prices are a central variable for earnings. IB Tomato reported in the first half of 2025 that falling gelatin prices gave a profitability signal, while noting that raw material prices are an external factor that calls for structural cost reduction.

Demand for health functional foods is rising with aging and health awareness, according to many analyses. However, health functional foods run on low margins, so a bigger share of them weighs on the overall operating margin. Customer diversification and price competition remain open issues.

Compared with biopharma players such as Samsung Biologics and Celltrion, which focus on contract manufacturing or biosimilars, Suheung's raw-material and capsule structure means a different demand profile and cycle.

06

Outlook

Disclosed quarterly results for January–September 2026 show diverging trends for revenue and profit. Operating profit went from KRW 21.2 billion in the first quarter to KRW 22.5 billion in the second and KRW 11 billion in the third.

Early-2026 outlooks from brokers pointed to revenue growth and profit recovery at the same time. The Korea IR Council presented this view in a report dated March 2, 2026, and did not state an investment rating or target price.

A securities analysis from the same period estimated 2026 consolidated revenue at KRW 755.5 billion, about 5% higher year on year, and operating profit at KRW 56.6 billion, about 13% higher. Hard-capsule revenue was projected at KRW 244.9 billion for 2026, growing about 7%.

The operating margin was expected to edge up from 7.0% in 2025 to about 7.5% in 2026. Cited growth drivers include the Vietnam expansion, exports of health functional foods to China and rising demand for gelatin and collagen raw materials.

WiseReport attributes continued growth to aging and rising demand for health functional foods. These estimates date from March 2026, so they should be read alongside the quarterly results disclosed since then.

The next points to check are the reasons behind the third-quarter profit decline, hard-capsule utilization in the second half, and the low-margin health-food share.

07

Valuation

PER
5.2×
PBR
0.4×
ROE
7.5%
EPS
₩3,319
BPS
₩45,779
Dividend per share
₩500

Valuation can be read along two axes: earnings trends and the price-to-book ratio. In 2023, operating profit and profit attributable to controlling shareholders fell sharply, which pushed the earnings multiple higher, and after the 2025 earnings recovery the multiple moved lower.

The price-to-book ratio currently sits below 1x. The Korea IR Council's March 2026 report said Suheung trades at a discount because of the limited profitability of health functional foods and customer concentration risk, and that the discount could narrow gradually if the main business units keep improving.

The same report described the diversified portfolio as more stable than peers. With profit attributable to controlling shareholders totaling KRW 37 billion over the last four quarters, the multiple should be read as the product of both price and earnings moves.

How the multiple is interpreted will depend on whether the earnings recovery continues beyond the fourth quarter of 2026.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Dominant domestic hard-capsule position

Its domestic hard-capsule share is reported at about 95%, and its global share is about 8%. It is described as the only domestic maker to have localized production and serves most domestic pharmaceutical firms.

Hard-capsule exports accounted for 77.31% of that segment's sales as of December 2025, giving it a channel to overseas demand.

Earnings recovery trend

Operating profit recovered from the KRW 33.8 billion low in 2024 to KRW 50.2 billion in 2025, up 48.3%. First-quarter 2026 operating profit was KRW 21.2 billion, up 340.5% from the prior quarter, and the second quarter added KRW 22.5 billion. Analysts say hard-capsule profitability recovered to the low-to-mid 10% range in the second half of 2025.

Export channels and production base

Analysts describe Chinese exports of health functional foods as growing fast. The Vietnam plant expansion is cited as a factor behind improved results, and demand for gelatin and collagen raw materials is also reported to be rising. Some forecasts expect the 2026 operating margin to edge up to about 7.5%.

09

Bear factors

Profit slowdown in the third quarter of 2026

Third-quarter 2026 revenue was KRW 188.4 billion, up only 1.8% year on year, while operating profit was KRW 11 billion, down 19.7%. Profit attributable to controlling shareholders was KRW 6.79 billion, down 24.4% year on year. Operating profit also fell 51.1% from the second quarter, so the quarterly profit trend has not stabilized.

Rising share of low-margin health foods

Health functional foods run on lower margins under the OEM/ODM model, so a larger share of them weighs on the overall operating margin. The 2025 operating margin of 7.0% is below the 9.8% of 2022. Hard-capsule profitability recovered in 2025, but the larger health-food share remains a margin burden.

Cost ratio pressure and customer concentration

The cost-of-sales ratio rose from 78.38% in 2022 to 84.20% in 2024, and the company cited higher raw material costs and stronger global competition. Analysts attributed the 2023 revenue decline partly to customer losses and lower orders. The Korea IR Council also pointed to customer concentration as a reason for the valuation discount.

10

Risk factors

Customer concentration and order volatility

Most domestic pharmaceutical firms and health-food makers are key customers, so order changes from a single client pass directly into revenue. In 2023, customer losses and lower orders reduced revenue to KRW 594.6 billion. The pace of customer diversification will shape earnings stability.

Raw material prices and export dependence

Gelatin and other raw material prices are an external factor that directly moves the cost ratio. Hard-capsule exports are a high share of sales, and the production base in Vietnam exposes the company to overseas demand and local operating conditions. The 84.20% cost ratio in 2024 shows this risk has already affected results.

Ownership structure and free float

Yang Ju-hwan and six related parties hold 52.83%, and treasury shares account for 3.74%, as of October 30, 2026. A filing in April 2026 reported that Woo Seung-hwan and a related party held 4.93%, with shares reduced through on-market sales. A limited free float can affect price volatility and trading liquidity.

11

What to watch next

  1. Around February 2027 (typical timing)

    Release of fourth-quarter and full-year 2026 preliminary results. Check whether operating profit for January–September 2026 (KRW 21.2 billion, KRW 22.5 billion and KRW 11 billion by quarter) carries through to the full year, and whether the full-year margin rises above 7.0% in 2025.

  2. By March 31, 2027

    Statutory deadline for filing the 2026 annual report. Review segment revenue mix, changes in the cost-of-sales ratio (84.20% in 2024), and the balance between health functional foods and hard capsules.

  3. Around the March 2027 annual shareholder meeting (date to be confirmed in filings)

    Confirm whether a year-end dividend is approved and the direction of shareholder returns. The 2026 meeting was held on March 27.

  4. Around mid-May 2027

    First-quarter 2027 results. Compare with first-quarter 2026 operating profit of KRW 21.2 billion, which was disclosed around May 15, to check quarterly continuity.

12

Overall view

Suheung is built around a domestic hard-capsule position of about 95% share, and its profit has moved from a low in 2024 back toward recovery since 2022.

On the disclosed figures, revenue reached KRW 722.3 billion in 2025, the largest year in 2022–2025, and operating profit rose from a KRW 33.8 billion low in 2024 to KRW 50.2 billion in 2025. Profit attributable to controlling shareholders grew in both 2024 and 2025, reaching KRW 43.5 billion.

Quarterly results, however, moved from KRW 21.2 billion and KRW 22.5 billion in the first two quarters of 2026 to KRW 11 billion in the third, so whether the recovery continues remains to be tested.

Bullish points include a near-dominant domestic position, a debt-to-equity ratio that fell from 97.2% in 2022 to 96.1% in 2025, Chinese exports of health functional foods and the Vietnam expansion.

Bearish points include a rising share of low-margin health functional foods, a higher cost-of-sales ratio and customer concentration. The price-to-book ratio sits below 1x, which should be read together with whether the earnings recovery holds.

The next checkpoints are the fourth-quarter 2026 results and the 2026 annual report, including its operating margin and segment mix.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. m.thinkpool.com
  2. comp.wisereport.co.kr
  3. ssl.pstatic.net
  4. eduinfom.com
  5. daily-stock-wiki.com
  6. ibtomato.com
  7. buffettlab.co.kr
  8. asp01.fnguide.com
  9. jobkorea.co.kr
  10. m.news.nate.com
  11. m.thinkpool.com
  12. comp.wisereport.co.kr
  13. dailyinvest.kr
  14. digitaltoday.co.kr
  15. news.nate.com
  16. digitaltoday.co.kr
  17. judal.co.kr
  18. judal.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis